作者: Jiongqiang Huang , Jingsong Chen , Rongchang Wang , Junfeng Huang , Mingkai Huang
DOI: 10.1016/J.CRITREVONC.2021.103308
关键词: KRAS 、 Pooled analysis 、 Metastasectomy 、 Medicine 、 Internal medicine 、 Oncology 、 Recurrence free survival 、 Colorectal cancer 、 Kras mutation 、 In patient 、 Meta-analysis
摘要: Abstract Background The purpose of the study was to evaluate whether KRAS mutation could be an independent prognostic biomarker in patients undergoing pulmonary metastasectomy (PM) for colorectal cancer (CRC). Methods A systemic review performed by searching online databases identify studies reporting overall survival (OS) and recurrence free (RFS) CRC PM. Pooled HRs were calculated OS RFS. Results total 15233 from 60 included. analysis showed that associated with worse (HR: 1.86, 95 % Cl: 1.35–2.57) RFS 1.68, 1.38–2.04). significant effect on and/or also shown other 18 factors. Conclusions This meta-analysis found is important predictor PM, supporting a comprehensive model including clinicopathological biological factors optimal selection prognosis surgical treatment.